Dystrophin Dp427 is lost due to multiple DMD intron retentions in rhabdomyosarcoma CRL-2061 cells
Dystrophin inactivation, responsible for Duchenne muscular dystrophy (DMD), is recently implicated as an anti-tumor suppressor factor in cancers with myogenic characteristics. Rhabdomyosarcoma (RMS), a mesodermal cancer, shows myogenic features and occurs at a higher frequency in mdx mouse, a DMD model mouse. In humans, as the clinical management of DMD advances to increase the life expectancy of patients, a subsequent issue is anticipated to be that of addressing other complications such as RMS.
Source: Neuromuscular Disorders - Category: Neurology Authors: E. Niba, R. Yamanaka, M. Abdul Qawee, H. Awano, M. Matsumoto, H. Nishio, M. Matsuo Source Type: research
More News: Brain | Cancer | Cancer & Oncology | Muscular Dystrophy | Neurology | Reflex Sympathetic Dystrophy | Rhabdomyosarcoma